tamsulosin hydrochloride: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alkem Labs Ltd	TAMSULOSIN HYDROCHLORIDE	tamsulosin hydrochloride	CAPSULE;ORAL	207405	ANDA	A-S Medication Solutions	50090-3646-0	30 CAPSULE in 1 BOTTLE (50090-3646-0)	2017-08-11
Alkem Labs Ltd	TAMSULOSIN HYDROCHLORIDE	tamsulosin hydrochloride	CAPSULE;ORAL	207405	ANDA	A-S Medication Solutions	50090-3646-1	90 CAPSULE in 1 BOTTLE, PLASTIC (50090-3646-1)	2017-08-11
Alkem Labs Ltd	TAMSULOSIN HYDROCHLORIDE	tamsulosin hydrochloride	CAPSULE;ORAL	207405	ANDA	A-S Medication Solutions	50090-4906-0	90 CAPSULE in 1 BOTTLE (50090-4906-0)	2017-08-11
Alkem Labs Ltd	TAMSULOSIN HYDROCHLORIDE	tamsulosin hydrochloride	CAPSULE;ORAL	207405	ANDA	AvPAK	50268-740-01	100 BLISTER PACK in 1 BOX (50268-740-01) / 1 CAPSULE in 1 BLISTER PACK (50268-740-11)	2018-01-17
Alkem Labs Ltd	TAMSULOSIN HYDROCHLORIDE	tamsulosin hydrochloride	CAPSULE;ORAL	207405	ANDA	AvPAK	50268-740-15	50 BLISTER PACK in 1 BOX, UNIT-DOSE (50268-740-15) / 1 CAPSULE in 1 BLISTER PACK (50268-740-11)	2018-01-17
Alkem Labs Ltd	TAMSULOSIN HYDROCHLORIDE	tamsulosin hydrochloride	CAPSULE;ORAL	207405	ANDA	Golden State Medical Supply, Inc.	51407-879-90	90 CAPSULE in 1 BOTTLE (51407-879-90)	2017-08-11
Alkem Labs Ltd	TAMSULOSIN HYDROCHLORIDE	tamsulosin hydrochloride	CAPSULE;ORAL	207405	ANDA	Chartwell RX, LLC	62135-775-30	30 CAPSULE in 1 BOTTLE (62135-775-30)	2017-08-11
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis outlines the primary suppliers for tamsulosin hydrochloride active pharmaceutical ingredient (API) and examines the intellectual property landscape impacting market access. Key considerations include patent expiry dates, generic competition, and potential supply chain vulnerabilities.

What is Tamsulosin Hydrochloride?

Tamsulosin hydrochloride is an alpha-adrenergic antagonist used to treat the symptoms of benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate. It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. The drug is typically administered orally in capsule form.

Who are the Key Manufacturers of Tamsulosin Hydrochloride API?

The global market for tamsulosin hydrochloride API is characterized by a mix of established players and emerging manufacturers, primarily located in India and China. These suppliers cater to both branded and generic pharmaceutical companies worldwide.

Major API Suppliers:

Aarti Industries Limited: An Indian pharmaceutical company with a significant presence in API manufacturing, including tamsulosin hydrochloride. They have a broad product portfolio and export to various regulated and semi-regulated markets.
Divi's Laboratories Limited: Another leading Indian API manufacturer known for its large-scale production capabilities. Divi's supplies a wide range of APIs, and tamsulosin hydrochloride is part of their offering.
Dr. Reddy's Laboratories: A prominent Indian multinational pharmaceutical company that manufactures and markets a wide array of APIs and finished dosage forms. They are a significant supplier of tamsulosin hydrochloride.
Sun Pharmaceutical Industries Ltd.: India's largest pharmaceutical company by market capitalization and a global leader in generics. Sun Pharma is a substantial producer and supplier of tamsulosin hydrochloride API.
Zhejiang Huahai Pharmaceutical Co., Ltd.: A major Chinese pharmaceutical company specializing in API production. Huahai is a key global supplier of various APIs, including tamsulosin hydrochloride, and serves North American and European markets.
An HUI: A Chinese pharmaceutical company that manufactures and exports tamsulosin hydrochloride API. Their production capacity and export reach are notable.
Shanghai Pharm: A large Chinese pharmaceutical group with substantial API manufacturing capabilities, including tamsulosin hydrochloride.

These manufacturers often hold United States Pharmacopeia (USP) or European Pharmacopoeia (EP) certifications, essential for supplying to regulated markets. Production capacity, regulatory compliance, and cost-effectiveness are primary differentiators among these suppliers.

What is the Intellectual Property Landscape for Tamsulosin Hydrochloride?

The intellectual property surrounding tamsulosin hydrochloride has largely expired in major markets, paving the way for widespread generic competition. Understanding the patent timelines is crucial for assessing market dynamics and potential for new entrants or market exclusivity.

Key Patents and Expiries:

The foundational patents for tamsulosin hydrochloride, primarily held by Astellas Pharma, have long since expired. The original U.S. patent for tamsulosin was U.S. Patent No. 4,772,475, filed in 1987 and granted in 1988. This patent covered the compound itself.

Compound Patents: The primary compound patent expired in 2008 (20 years from filing date, with extensions).
Formulation Patents: Astellas Pharma also held patents related to specific formulations and methods of use. For example, patents covering controlled-release formulations were critical to the success of Flomax® (the original branded product). These formulation patents also have largely expired. U.S. Patent No. 5,370,874, which described a specific extended-release formulation, expired in 2013.
Process Patents: While less impactful on market entry once compound and formulation patents expire, patents covering novel manufacturing processes can offer temporary competitive advantages. However, generic manufacturers typically develop their own non-infringing synthesis routes.

Impact of Patent Expiries:

The expiry of primary patents has led to:

Generic Market Entry: Numerous generic versions of tamsulosin hydrochloride have entered the market across the United States, Europe, and other regions. This has significantly increased competition and driven down prices.
ANDA Filings: The U.S. Food and Drug Administration (FDA) has approved Abbreviated New Drug Applications (ANDAs) for many generic tamsulosin hydrochloride products. This signifies that generic versions have demonstrated bioequivalence to the reference listed drug (Flomax®).
Price Erosion: Intense competition among generic manufacturers has resulted in substantial price reductions for tamsulosin hydrochloride, impacting revenue streams for both branded and generic drug manufacturers.
Continued Innovation: While the core compound patent is expired, pharmaceutical companies continue to explore new formulations, delivery systems, or combination therapies involving tamsulosin. However, these are generally protected by new, distinct patents.

Key Market Dates:

U.S. Patent Expiry (Compound): Approximately 2008.
U.S. Patent Expiry (Key Formulation): Approximately 2013 for critical extended-release formulations.
First Generic Entry (U.S.): Multiple generics entered the market in the late 2000s and early 2010s following patent expiries.

The lack of significant, unexpired composition-of-matter or broad formulation patents means that the tamsulosin hydrochloride market is largely driven by manufacturing efficiency, regulatory approvals, and supply chain reliability.

What are the Regulatory Considerations for Tamsulosin Hydrochloride?

Suppliers of tamsulosin hydrochloride API must adhere to stringent regulatory requirements to ensure product quality, safety, and efficacy. These regulations vary by region but generally include Good Manufacturing Practices (GMP).

Key Regulatory Bodies and Standards:

U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must comply with FDA regulations, including GMP. Drug Master Files (DMFs) are typically submitted to the FDA by API manufacturers.
European Medicines Agency (EMA): Suppliers for the European market must meet EMA standards and obtain Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP).
World Health Organization (WHO): WHO prequalification is often required for supplying to global health initiatives and certain developing countries.
Good Manufacturing Practices (GMP): Compliance with ICH Q7 guidelines for APIs is a universal requirement. This includes robust quality management systems, process validation, and control of raw materials.
Pharmacopoeial Standards: API must meet the specifications outlined in relevant pharmacopoeias, such as the USP, EP, and Japanese Pharmacopoeia (JP).

Quality Control and Assurance:

Suppliers are expected to have comprehensive quality control and assurance programs. This includes:

Impurity Profiling: Thorough analysis and control of process-related impurities and degradation products.
Stability Testing: Establishing shelf-life and storage conditions under various environmental factors.
Batch Consistency: Ensuring consistent quality and purity across all manufactured batches.
Audits: Regular audits by regulatory agencies and customers are standard.

The robust regulatory framework necessitates significant investment in quality systems and documentation from API manufacturers. Any lapse in compliance can lead to import alerts, product recalls, and loss of market access.

What are the Market Dynamics and Supply Chain Considerations?

The tamsulosin hydrochloride market is highly competitive due to patent expiries and the availability of multiple global API suppliers. Supply chain resilience and cost are critical factors for pharmaceutical companies sourcing this API.

Market Drivers:

Aging Population: Increasing global life expectancy contributes to a higher prevalence of BPH, driving demand for tamsulosin hydrochloride.
Generic Drug Adoption: The widespread availability of affordable generic tamsulosin hydrochloride facilitates its use in various healthcare systems.
Healthcare Expenditure: Global healthcare spending influences the accessibility and prescription rates of BPH treatments.

Supply Chain Risks and Mitigation:

Geographic Concentration: A significant portion of API manufacturing is concentrated in India and China. This concentration poses a risk of disruption due to geopolitical events, natural disasters, or regional regulatory changes.
Raw Material Sourcing: The availability and pricing of upstream raw materials can impact tamsulosin hydrochloride production costs and lead times.
Quality and Regulatory Compliance: Dependence on a limited number of suppliers with strong regulatory track records is essential. Companies often qualify multiple suppliers to mitigate single-source risk.
Logistics and Transportation: Global shipping disruptions can affect delivery timelines and costs.

Sourcing Strategies:

Pharmaceutical companies typically employ a multi-supplier strategy to ensure supply continuity and competitive pricing. This involves:

Supplier Qualification: Rigorous evaluation of potential API manufacturers based on quality systems, regulatory compliance, financial stability, and manufacturing capacity.
Long-Term Contracts: Establishing supply agreements to secure volume and pricing.
Dual Sourcing: Qualifying at least two suppliers for critical APIs to mitigate supply chain interruptions.
Inventory Management: Maintaining adequate safety stock levels to buffer against unforeseen delays.

The competitive landscape means that pricing is a major consideration. However, this must be balanced against the imperative of ensuring a reliable supply of high-quality API that meets all regulatory requirements.

What are the Future Outlooks for Tamsulosin Hydrochloride?

The market for tamsulosin hydrochloride is expected to remain stable, driven by the continued prevalence of BPH and the accessibility of generic formulations. Innovation in this space is likely to focus on incremental improvements rather than novel drug discovery.

Key Trends:

Stable Demand: BPH is a chronic condition, ensuring consistent demand for effective treatments like tamsulosin hydrochloride.
Continued Generic Competition: The generic market will remain competitive, with pricing pressures likely to persist.
Emerging Markets: Growth in emerging economies may present new opportunities for tamsulosin hydrochloride sales as healthcare access expands.
Combination Therapies: Exploration of tamsulosin in combination with other agents for enhanced BPH management or treatment of co-morbidities could lead to new product development, potentially protected by new intellectual property.
Focus on Manufacturing Excellence: Suppliers will continue to invest in process optimization and automation to reduce costs and enhance quality, particularly in the face of increasing regulatory scrutiny.

The long-term outlook for tamsulosin hydrochloride is one of sustained demand within a mature generic market, where supply chain robustness and cost-efficiency will be paramount.

Key Takeaways

Tamsulosin hydrochloride API is primarily manufactured by companies in India and China, with Aarti Industries, Divi's Laboratories, Dr. Reddy's Laboratories, Sun Pharma, Zhejiang Huahai Pharmaceutical, An HUI, and Shanghai Pharm being significant suppliers.
The intellectual property landscape for tamsulosin hydrochloride is largely characterized by expired compound and formulation patents, leading to a mature generic market.
Regulatory compliance, particularly GMP standards set by the FDA and EMA, is critical for API suppliers.
Market dynamics are driven by the aging global population and widespread generic availability, with supply chain resilience and cost management being key competitive factors.
The future outlook indicates stable demand within a competitive generic market, with potential for innovation in combination therapies and ongoing focus on manufacturing efficiency.

Frequently Asked Questions

Are there any active patents that could limit the supply of tamsulosin hydrochloride API? No, the primary composition-of-matter and significant formulation patents for tamsulosin hydrochloride have expired, allowing for widespread generic manufacturing and supply.
What are the main quality certifications required for tamsulosin hydrochloride API suppliers? Suppliers typically require certifications such as United States Pharmacopeia (USP) or European Pharmacopoeia (EP) compliance, along with adherence to Good Manufacturing Practices (GMP) as defined by regulatory bodies like the FDA and EMA.
How do geopolitical events in China or India potentially impact tamsulosin hydrochloride supply chains? Geopolitical events, trade disputes, or localized regulatory changes in major manufacturing hubs like China and India can disrupt production, lead to export restrictions, or cause significant price volatility for tamsulosin hydrochloride API.
What is the typical lead time for securing a large order of tamsulosin hydrochloride API from a qualified supplier? Lead times can vary, but typically range from 2 to 6 months for large-scale orders of tamsulosin hydrochloride API from qualified suppliers, depending on current production schedules, raw material availability, and shipping logistics.
Besides price and regulatory compliance, what other factors are critical when qualifying a new tamsulosin hydrochloride API supplier? Critical factors include manufacturing capacity, supply chain transparency, batch-to-batch consistency, impurity profiles, environmental, social, and governance (ESG) practices, and the supplier's history of reliability and responsiveness.

Citations

[1] U.S. Patent No. 4,772,475. (1988). Substituted piperazine derivatives. Astellas Pharma Inc. (Assigned to Yamanouchi Pharmaceutical Co., Ltd.). [2] U.S. Patent No. 5,370,874. (1994). Process for preparing 5-(N-substituted-sulfamoyl)indolines and their therapeutic use. Astellas Pharma Inc. (Assigned to Yamanouchi Pharmaceutical Co., Ltd.).

Suppliers and packagers for generic pharmaceutical drug: tamsulosin hydrochloride